Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies - Summary - MDSpire

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • By

  • Sigrun Einarsdottir

  • Stephanie Lobaugh

  • Danny Luan

  • Marina Gomez-Llobell

  • Padmapriya Subramanian

  • Sean Devlin

  • David Chung

  • Parastoo B. Dahi

  • Lorenzo Falchi

  • Sergio Giralt

  • Heather Landau

  • Alexander M. Lesokhin

  • Richard Lin

  • Jennifer Lue

  • Sham Mailankody

  • M. Lia Palomba

  • Jae H. Park

  • Gilles Salles

  • Michael Scordo

  • Silvia Escribano-Serrat

  • Jaime Sanz

  • Kai Rejeski

  • Roni Shouval

  • Saad Usmani

  • Miguel-Angel Perales

  • Gunjan Shah

  • Zainab Shahid

  • July 2, 2025

  • 0 min

Share

Objective:

To investigate humoral immunity and vaccine responses to 12 vaccine-preventable infections in patients treated with CAR T-cell therapy, highlighting the significance of these responses in clinical outcomes.

Key Findings:
  • CD19 CAR T-cell therapy leads to nearly universal CD19 + B cell aplasia, while BCMA CAR T-cell therapy specifically depletes plasma cells.
  • Response rates to mRNA vaccines against COVID-19 were 27-34% for CD19 CAR recipients.
  • BCMA CAR T-cell recipients had lower seroprotection rates against vaccine-preventable infections compared to CD19 CAR T-cell recipients.
  • A significant percentage of infections post BCMA CAR T-cell therapy were vaccine preventable.
Interpretation:

The study highlights the distinct humoral deficiencies in patients receiving CD19 versus BCMA CAR T-cell therapies and underscores the need for tailored vaccination strategies.

Limitations:
  • Retrospective design may introduce bias.
  • Variability in clinical testing practices and timing of patient follow-up.
Conclusion:

Vaccination is crucial for infection prevention in CAR T-cell therapy recipients, and further studies are needed to optimize vaccination strategies post-treatment.

Original Source(s)

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

  • by Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian, Sean Devlin, David Chung, Parastoo B. Dahi, Lorenzo Falchi, Sergio Giralt, Heather Landau, Alexander M. Lesokhin, Richard Lin, Jennifer Lue, Sham Mailankody, M. Lia Palomba, Jae H. Park, Gilles Salles, Michael Scordo, Silvia Escribano-Serrat, Jaime Sanz, Kai Rejeski, Roni Shouval, Saad Usmani, Miguel-Angel Perales, Gunjan Shah, Zainab Shahid

  • July 2, 2025

Related Content

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Impairment of Circulating Follicular Helper T Cells in HIV-Positive Individuals Who Are Negative for Hepatitis B Surface Antibody Despite Vaccination

Breakthrough infections in MPN-COVID vaccinated patients